Location permission needed for a better experience.
How can we help you?
EN
Hızlı Randevu
Hastane
Randevusu
Görüntülü Görüşme Randevusu
Education
  • 2012 Yeditepe University Faculty of Medicine / Professor
  • 2006 Yeditepe University Faculty of Medicine / Associate Professor Doktor
  • 2004 Hacettepe University Faculty of Medicine Tıbbi Onkoloji
  • 2004 European Certification in Medical Oncology
  • 2001 Hacettepe University Faculty of Medicine İç Hastalıkları
  • 1996 Hacettepe University Faculty of Medicine
Experience
  • 2021 - 2024 Onkoloji ve İmmunoterapi Association/ Başkan
  • 2023 Acıbadem Healthcare Services
  • 2017 Dana Farber/Partners Cancer Çare Oncology Visiting Physician Program, Boston
  • 2017 Acibadem University Faculty of Medicine / Professor
  • 2016 Acıbadem Healthcare Services
  • 2014 - 2016 Türk Tıbbi Onkoloji Association (TTOD)/ Genel Sekreteri
  • 2012 - 2016 Yeditepe University Faculty of Medicine / Professor
  • 2006 - 2012 Yeditepe Ünivestitesi Faculty of Medicine /Associate Professor
  • 2004 - 2006 Yeditepe Ünivestitesi Faculty of Medicine /Associate Professor
  • 2001 - 2004 Hacettepe University Onkoloji Institute// Tıbbi Onkoloji
  • 2000 - 2001 Hacettepe University Onkoloji Institute// Tıbbi Onkoloji
  • 1997 - 2001 Hacettepe University Faculty of Medicine / İç Hastalıkları
  • 1996 Hacettepe University Faculty of Medicine / İç Hastalıkları
Memberships
  • Europen Society of Medical Oncology (ESMO)
  • Türk Tıbbi Onkoloji Association ( TTOD)
  • American Society of Clinical Oncology (ASCO)
  • Türk Hematoloji Association (THD)
  • Türk İç Hastalıkları Uzmanlık Association
  • Türk Tabipler Birliği, İstanbul Tabip Odası
  • İstanbul Meme Hastalıkları Association
  • Türk Onkoloji Grubu Association (TOG)
PUBLICATIONS
  • Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer BMC Cancer. 2024 Jan 2;24(1):16.
  • A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non- small celi lung cancer patients and crizotinib efficacy Lung Sub-Group Study of the Turkish Oncology Group. Medicine (Baltimore). 2024 May 24;103(21):e3797
  • Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study Expert Opin Pharmacother. 2024 Mar; 25(4):477-484.
  • Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2- negative metastatic breast cancer Future Oncol. 2023 May 3.
  • Immunotherapy for Lung Cancer J Oncol Sci. 2023;9(2):97-111.
.
.
.

Contact Us

Fill out the form below for your information requests

As Acıbadem Healthcare Group, you can report your requests, suggestions, thanks and complaints by filling out the form below or by contacting us at +90 538 685 39 52 so that we can provide you with a better and higher quality service.

See More
See More
Security Code

INFORMATION NOTICE ON THE PROCESSING OF PERSONAL DATA

Acıbadem Sağlık Hizmetleri ve Ticaret A.Ş. and its controlling and affiliated companies listed in Annex-1 (each referred to individually as the "Company" and collectively as the "Companies") process your general and/or special category personal data (including but not limited to health data) ("Personal Data") in the capacity of Data Controller under the Personal Data Protection Law No. 6698 ("Law") and related legislation. Processing of Personal Data is carried out in accordance with the framework outlined below and in compliance with the Fundamental Law on Health Services No. 3359, the Decree Law No. 663 on the Organization and Duties of the Ministry of Health and its Affiliated Institutions, the Regulation on the Provision of Remote Health Services, the Private Hospitals Regulation, the Ministry of Health regulations, and other relevant legislation.

I. Acquisition, Processing, and Purposes of Processing Personal Data

Your Personal Data is obtained through verbal, written, visual, or electronic channels (such as our website, mobile applications, and call center) for the purposes of protecting public health, preventive medicine, medical diagnosis, treatment and care services, and the planning and management of healthcare services and their financing, in alignment with the Company's fields of activity. The Personal Data processed by the Company, including but not limited to the following, is collected and processed proportionally and in connection with these purposes:

Your Personal Data may be processed under the conditions specified in Articles 5 and 6 of the Law for the following purposes:

II. Transfer of Personal Data

Your Personal Data may be shared with:

III. Method and Legal Basis for Collecting Personal Data

Your Personal Data is collected through verbal, written, visual, or electronic means for the lawful execution of the Company's activities and compliance with contractual and legal obligations. The legal basis for collection includes:

As per Article 6 - (3) of the Law, personal data related to health and sexual life may be processed without explicit consent by persons or institutions subject to confidentiality obligations for public health protection, preventive medicine, medical diagnosis, treatment, and care services, as well as the planning and management of healthcare financing.

IV. Your Rights Regarding the Protection of Personal Data

Under Article 11 of the Law, you have the right to:

V. Data Security

The Companies ensure the security of Personal Data by implementing necessary technical and administrative measures in accordance with information security standards and procedures.

VI. Complaints and Contact Information

To exercise your rights under the Law, you may submit a request through the methods specified in the "Acıbadem Sağlık Hizmetleri ve Ticaret A.Ş. Data Subject Application Form" available at https://www.acibadem.com.tr/acibademonline/images/Ac%C4%B1badem_Veri_Sahibi_Basvuru_Formu.pdf.

Requests can be submitted by mail, notarized document, or secure electronic means to:

ANNEX-1: List of Companies

 

TOP x""